NCT03629327View on ClinicalTrials.gov

Inducing Immune Quiescence the Genital Tract With ASA

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions
HIV
Interventions
DRUG

ASA 81mg

Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months

OTHER

Control Group

Participants will be randomized to take nothing on a daily basis for a duration of 6 months

DRUG

ASA 325mg

Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months

Trial Locations (1)

Unknown

RECRUITING

Kenyan Aids Control Project/University of Nairobi, Nairobi

All Listed Sponsors
lead

University of Manitoba

OTHER